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ABSTRACT
Objective: Methicilin resistant Staphylococcus aureus (MRSA) leads a serious major problem such as well as nosocomial infection especially in clinical 
burn setting. Management of MRSA infection becomes more complex in clinical settings due to its extension of resistance towards much class of 
antibiotics and it is purely based on antibiotic susceptibility. This case report assesses the efficacy combination of fosfomycin and amikacin in the 
management of MRSA infection in a burn patient.
Methods: A 31-year-old male was transferred to the burn center for definitive treatment. Initially, the patient was treated with ceftazidime injection 
as empiric antibiotic 1 g 3 times daily, but the patient became sepsis during the treatment. Blood specimen was taken and MRSA was isolated from 
this culture. The patient was isolated and based on antibiotic susceptibility, the patient was started on fosfomycin 2 g IV twice daily for first 7 days, 
and after that fosfomycin was combined with amikacin IV 500 mg once daily.
Results: After administration of these antibiotics, a rapid clinical improvement was observed with the patient, leucocytosis did not occur and blood 
culture was negative. The patient completed a total of 14 days of fosfomycin and 8 days of amikacin therapy. 
Conclusion: The synergistic combination of fosfomycin with amikacin, may be useful alternative treatment option for sepsis related MRSA in burn 
injury. Further research is also needed to clarify effectiveness of fosfomycin and amikacin to treat MRSA infection in burn patient.
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INTRODUCTION
Infections caused by methicillin-resistant Staphylococcus aureus 
(MRSA) are a frequent occurrence in most medical centers, especially 
in patients admitted to the intensive care (IC) unit for prolonged 
periods of time [1]. In burned individuals, death due to the failure 
of initial resuscitation has been uncommon in recent years. Sepsis, 
despite the advent of potent new antibiotics, is now the major cause 
of death in these patients. The appearance of drug-resistant organisms 
is a common consequence of the injudicious use of antimicrobials, as 
exemplified by the emergence of MRSA [2].
MRSA, which always exhibits multiple antibiotic resistance in clinic 
manifestation, is one of the most important pathogenic species that may 
result in a severe shock to death [3]. To the best of our knowledge, severe 
burn patients are more susceptible to MRSA infection because of losing 
the protective skin barrier and immunological variations. The outbreak 
of MRSA infection in burn patients has been widely reported, and the 
persistence of MRSA in burn units has been proved by more and more 
evidence [4]. In the past few years, the prevalence of MRSA isolated from 
clinical isolates, especially in burn patients, increased sharply in China [5].
Historically vancomycin, a glycopeptide antimicrobial, has been the 
treatment of choice for MRSA infections. However, the clinical utility 
of vancomycin has recently been questioned when employed in the 
treatment of MRSA infections when the mean inhibitory concentration 
(MIC) of vancomycin is >1 mg/L, with published literature reporting 
increased treatment failure and mortality in patients due to 
inability to attain currently established pharmacokinetic (PK) and 
pharmacodynamic (PD) targets [6,7].
Although antimicrobials such as vancomycin have been shown to 
be effective in controlling MRSA infection, MRSA remains a common 
cause of death in burn patients. Fosfomycin was described originally 
by Hendlin and associates more than three decades ago. Fosfomycin 
was effective in controlling infection caused by MRSA, especially when 
combined with other antimicrobial agents [8,9]. We described a case 
of MRSA in a patient with scald burn injury who did not respond to 
initial ceftazidime therapy but responded clinically to treatment with 
fosfomycin-amikacin.
PRESENTATION OF CASE
A 31-year-old male sustained scald burn at the steam-powered 
electric generator in August 2016. He was conservatively managed 
including debridement at once in a private hospital at Pati, Centre of 
Java and brought to the Dr. Soetomo Hospital for further management. 
At admission, he was at the 9th day after the injury. On general 
examination, the patient was conscious, oriented, afebrile, not anemic, 
normal leukocyte and albumin level, not a known history of diabetes 
mellitus or hypertension and not sepsis. On local examination, he was 
diagnosed at 37.5% 2nd degree burns present in regimen facialis with 
burned eyelashes, thoracoabdominalis, extrimitas superior, extrimitas 
inferior, and genitalia externa.
Initially, the patient was treated with injection ceftazidime intravenously 
(IV) 1 g 3 times daily for 7 days along with supportive drugs, and during 
the hospitalization, surgery (debridement) was done for 3 times. 
Wound debridement was done under closely supervised by plastic 
surgeon and anesthesiologist. Soon after the debridement, wound 
was treated with a dressing containing silver. The patient completed 
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a total of 7 days of ceftazidime, but at 5th days of ceftazidime therapy, 
the patient became leukocytosis (>27.103) and fever and diagnosed 
as bacteremia or sepsis. It seems that the patient unresponsive to 
ceftazidime. Blood specimen was taken from the right and left venous 
vessel aseptically and processed by microbiological procedures. MRSA 
was isolated in culture. Antibiotic susceptibility was performed by 
Kirbi–Bauer disk diffusion method where the isolate was found to 
be sensitive to tetracyclin, erytromicin, clindamycin, quinupristin-
dalfopristin, fosfomycin, and vancomycin. The isolate of MRSA was 
found to be resistant to  gentamicin, ampicillin, ampicillin-sulbactam, 
penicillin G, oxacillin, chloramphenicol, levofloxacin, and moxifloxacin. 
The patient was isolated and treated with injection fosfomycin 2 g IV 
twice daily for the first 7 days and after that fosfomycin was combined 
with amikacin IV 500 mg once daily. The patient completed a total of 
14 days of fosfomycin and 8 days of amikacin therapy. At the end of 
antibiotics therapy, blood specimen was taken, and the bacterial culture 
was negative.
DISCUSSION
MRSA is a widespread pathogen both in the community and in hospital 
settings. Infection of burn wound patients with MRSA and pathogen 
causes higher morbidity and mortality which may contribute death 
in about three-fourths of the burn wound infected patients [10]. Due 
to imprudent uses and suboptimal doses of antibiotics, common 
pathogenic microorganism develops antimicrobial resistance against 
commonly used drugs. It increases the burden of the patient as well as 
national cost in the health-care sectors. In our study, MRSA was isolated 
from the scald burn patient. In burns, breaching skin barriers provide a 
suitable site for bacterial multiplication and are more persistent richer 
sources of infection than any other surgical wounds, mainly because 
of the larger area involved and longer duration of patient stay in the 
hospital [11].
For this reason, special attention to hospital infection should be paid 
in burns unit by early interventions should be performed to improve 
the quality of treatment. Antibiotics are frequently administered 
at random, without obtaining the results or without respect to the 
principles of rational antibiotic therapy. On the other hand, the usage 
of antibiotics is one of the main risk factors for nosocomial infections. 
Excessive use of antibiotics stimulates the development of antibiotic-
resistant bacteria, increases treatment costs, and causes side effects. 
This can be avoided by rational use of antimicrobials, i.e., only when 
necessary, with a careful choice of the suitable drugs [12]. Methicillin 
resistance in S. aureus is a gold standard for multidrug resistance, 
mainly to penicillin family (such as cephalosporins, ampicillin, and 
amoxicillin), ticarcillin-clavulanic acid, piperacillin-tazobactam, and the 
carbapenems regardless of the susceptibility testing results [13,14] and 
our report also supports the same.
To date, there only have been limited data on MRSA in Indonesia. An early 
study conducted in 2001 identified 1 (0.3%) MRSA isolates among 329 
S. aureus nares flora from 3,995 patients [15]. By 2011, in three teaching 
hospitals (Denpasar, Semarang, and Malang) in Indonesia, screening of 
1,502 surgery patients at the time of discharge by culturingnares, throat 
and skin lesion, revealed a MRSA carriage rate of 4% [16]. Our patient 
with diagnosed as 37.5% 2nd degree burn, categorized as a severe burn. 
In the case of a severe burn, the probability of MRSA infection increases, 
since the patients spend more time in the hospital, and undergo more 
frequent debridements and dressings [17]. The similar thought applies 
to surgical procedures. It could be argued that the severity of the burns 
itself was the reason for additional operation, which, in turn, increased 
the risk to test positive for MRSA [18].
Ceftazidime is widely used to treat burn patients, but few data are 
available on its PKs in this group. The standard dosage recommendations 
for beta-lactam antibiotics can result in very low drug levels in IC 
patients and burn patients in the absence of renal dysfunction. In this 
study, the patient was given ceftazidime 1 g 3 times daily but showed no 
signs of clinical improvement. Alteration in the physiological response 
to a burn makes dosing medication, especially antibiotics, challenging 
in burn patients.
A study by Conil et al., 2007, carried out the PKs of ceftazidime in burn 
patients with daily doses of 1 g × 6 (n=17). The results showed that the 
ratio of C (min) to the low MIC breakpoint (4 mg/l) was lower than 4 in 
52% of subjects receiving ceftazidime. The C (min) of ceftazidime was 
correlated with measured creatinine clearance (CLCR) and was higher 
in mechanically ventilated patients than in non-ventilated patients. The 
clearance of ceftazidime was correlated with age. Therefore, dosage 
adjustment of these drugs in burn patients needs to take into account 
age, measured CLCR and the danger of low concentrations occurring 
when the CLCR is >120 ml/min. In burn patients, the PK disposition of 
ceftazidime was much more variable than in healthy subjects. Age and 
CLCR were predictors of the disposition of this antibiotics. Shortening 
the dosage interval or using continuous infusions will prevent low 
serum levels and keep trough levels above the MIC for longer periods 
of time [19].
Fosfomycin has a broad spectrum of activity against a wide range of 
Gram-positive and Gram-negative bacteria. Its unique mechanism of 
action may provide a synergistic effect to other antibiotics including 
beta-lactams, aminoglycosides, and fluoroquinolones [20-22] 
Recently, intravenous fosfomycin has been administered in critically ill 
patients with sepsis or nosocomial-acquired infections due to MRSA, 
vancomycin-resistant Enterococcus, and MDR Gram-negative bacteria, 
especially carbapenem-resistant Klebsiella pneumoniae, in combination 
with other antibiotics, due to its unique mechanism of action and its 
protective effect against nephrotoxicity induced by aminoglycosides 
or colistin [23-25]. Rationale for combining fosfomycin with a second 
antimicrobial agent is to prevent the emergence of fosfomycin resistant 
strains. Fosfomycin is approved in several European countries for the 
therapy of soft tissue infections and sepsis. In our patient, amikacin 
500 mg daily was administered with fosfomycin.
In healthy subjects, amikacin exhibits low protein binding (<10%) and 
a volume of distribution of 0.20–0.25 L/kg. Unmetabolized amikacin is 
eliminated in an active form through renal mechanisms, essentially by 
glomerular filtration. PK changes noted in burn patients are an increased 
volume of distribution and altered renal clearance [26]. Due to the PK 
alterations observed in burn patients, inadequate peak concentrations 
(Cmax) are frequent when using multiple-daily dosing regimens [27]. 
Aminoglycosides exhibit a concentration-dependent bactericidal effect, 
and many reports have shown the merits of once-daily dosing (ODD) 
regimen [28,29]. The ODD regimen is based on PD, bacteriological, and 
toxicological principles. It enables optimization of the Cmax/MIC ratio as 
well as efficacy while ensuring an “aminoglycoside-free” period during 
a 24 h interval, thus decreasing toxicity [30-32]. In this study, amikacin 
was administered 500 mg once daily. Our study is similar to Conil 
et al., who recorded plasma concentration following administration of 
20 mg/kg amikacin in burn patients. It conclude that ODD regimens of 
amikacin in patients with burns >15% body surface area and/or with 
ClCR >120 ml/min could require doses >20 mg/kg to reach adequate 
Cmax [33]. Amikacin is one of a aminoglycosides antibiotics, clearance of 
aminoglycosides was increased in burns patients that caused lower Cmax 
values and loss of aminoglycosides was caused by greater percentage 
total body surface area [33,34].
Swab specimen was taken by several days of antibiotics administration, 
and Acinetobacter baumannii was found from this swab. Antibiotic 
susceptibility was performed and the isolate resistant to amikacin, 
tobramycin, gentamycin, astreonam, amoxicillin-clavulanic acid, 
cefazoline, ceftazidime, cefotaxime, ceftazidime, cefoperazone-sulbactam, 
tetracycline, ciprofloxacin, levofloxacin, fosfomycin, meropenem, and 
ertapenem. Although the bacteria are resistant to fosfomycin and 
amikacin, at the end of these antibiotics therapy for 14 days, blood 
specimen was taken, and the bacterial culture was negative.
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A study by Montgomery et al. showed that for A. baumannii strains, 
the effect was most pronounced for strains with high amikacin 
resistances (MIC >1024 µ/ml), but amikacin MIC values were reduced 
<256 µ/ml with the amikacin/fosfomycin combination. It concluded 
that combining amikacin in a 5:2 ratio with fosfomycin significantly 
enhanced the potency of amikacin-resistant pathogen [35].
CONCLUSION
MRSA acquisition remains a significant problem in burn units. We 
describes a case of a scald burn injury patient who successfully treated 
with fosfomycin 2 g every 12 h and amikacin 500 mg once daily 
for documented MRSA sepsis. Larger studies are needed to further 
evaluate for safety, efficacy, and the appropriate dose based on PKs 
altered in burn patients. Clinicians should recognize the rational use 
of antibiotics, adjust treatment accordingly, thus allowing for improved 
patient outcomes.
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